Retatrutide benefits beyond weight loss: liver fat, blood pressure

Retatrutide’s trial record gets reduced to one number: 24.2% weight loss at 48 weeks on the highest dose, the figure everyone quotes. That number is real, but it buries the more interesting part of the phase 2 program. The same trials, plus a dedicated liver-disease substudy, measured liver fat, lipid particles, blood pressure, glycemic control and even how hungry people felt, and several of those effects look larger, and mechanistically more distinct, than the headline weight number suggests. Two phase 3 trials have since confirmed the weight and glucose effects at a bigger scale. Neither one touched the liver, the lipids or the blood pressure.

Bottom line: the most dramatic number in retatrutide’s entire data set is an 80%-plus drop in liver fat, bigger in relative terms than the 24% weight-loss figure everyone quotes, and it comes from a substudy most casual readers never see.

The liver fat number is the most dramatic one in the data set

A phase 2a substudy enrolled 98 adults who had metabolic dysfunction-associated steatotic liver disease (MASLD) and at least 10% liver fat, then randomized them to 48 weeks of retatrutide or placebo. At 24 weeks, liver fat (measured by MRI proton density fat fraction, not an estimate) fell in a clean dose-response line: 42.9% at the 1 mg dose, 57.0% at 4 mg, 81.4% at 8 mg and 82.4% at 12 mg, against a 0.3% increase on placebo^[1]. Every comparison hit p<0.001.

82.4% relative drop in liver fat at 24 weeks on the 12 mg dose, vs a 0.3% rise on placebo PMID 38858523

Put a number on what that meant for the people in the trial:

Liver fat response by dose, 24 weeks

Phase 2a MASLD substudy, n=98.

Four out of five people on the top dose went from fatty liver disease to a normal liver fat scan in six months^[1]. That same trial’s dose-response curve, run again at 24 weeks instead of 48, was steep enough that the 8 mg and 12 mg groups were already statistically indistinguishable from each other, the same ceiling-effect shape seen in the trial’s weight-loss curve^[1].

Lipids and blood pressure moved too, just not the number people expect

In a post hoc analysis of two retatrutide phase 2 trials (one in obesity alone, one in obesity with type 2 diabetes), higher doses produced placebo-adjusted reductions in triglyceride-rich lipoprotein cholesterol of up to 29.4% to 38.6%, along with reductions in non-HDL cholesterol and apolipoprotein B, the lipid markers most tied to cardiovascular risk^[2].

That’s not the same thing as a standard triglyceride reading. The study measured lipoprotein particle subclasses, the markers cardiologists rely on to judge atherosclerotic risk, not the single number on a routine lipid panel. It’s a more precise result than “triglycerides went down,” and arguably a more useful one.

Blood pressure is murkier. A meta-analysis of 85 placebo-controlled incretin-therapy trials (90,977 participants) found that triple-receptor agonists, the class retatrutide currently defines alone in human data, produced the largest pooled blood-pressure drop of any incretin category: 6.6 mmHg systolic and 2.1 mmHg diastolic, roughly double what GLP-1-only drugs managed^[3]. That’s a real number, but it’s a pooled class estimate, not retatrutide’s own trial reported in isolation. Nobody has published that isolated figure yet.

The part people on the drug ask about: hunger, not the scale

The Reddit post behind this article put it plainly: for one user, the biggest benefit of retatrutide wasn’t the weight loss, it was the mental space that came with not thinking about food constantly. A validated questionnaire inside a real trial backs that up.

A pre-specified exploratory analysis inside the phase 2 type 2 diabetes trial (n=275) tracked appetite and eating behavior with two validated questionnaires, the Appetite Visual Analogue Scale and the Eating Inventory. By week 24, participants on 4 mg or higher reported significantly less hunger, less overall appetite and less anticipated food intake than those on placebo^[4]. The 8 mg and 12 mg groups also scored lower on “Disinhibition,” the Eating Inventory’s measure of the tendency to overeat, and the 12 mg group scored higher on conscious dietary restraint by week 36. Those behavioral shifts correlated with how much weight people lost (r = 0.28 to 0.36)^[4].

• What this does establish: a validated, pre-specified questionnaire found less hunger and less disinhibited eating on higher doses.
• What it doesn’t establish: whether that effect is independent of weight loss itself, or just how it feels partway through losing 15% of your body weight. The correlation data can’t separate cause from consequence.

Why a third receptor changes more than the number on the scale

Retatrutide is a single synthetic peptide built to agonize three receptors at once: GIP, GLP-1 and glucagon. Semaglutide works through GLP-1 alone; tirzepatide adds GIP but not glucagon^[1]. Glucagon is the odd one out, because unlike the other two, its receptor isn’t primarily about insulin or satiety.

In diet-induced obese mice, glucagon-receptor agonism increased hepatic fatty acid oxidation and whole-body energy expenditure, and it did so through a pathway that required intact liver FXR signaling: knock out that receptor in the liver and the metabolic benefit disappeared even though the drug was still on board^[5]. That finding comes from mice. It still maps onto a mechanism GLP-1-only signaling never touches. The honest version of the story is that retatrutide’s extra receptor is the proposed explanation for why its liver-fat number dwarfs what GLP-1-only drugs report. No trial has tested retatrutide against a GLP-1-only drug head to head on liver fat specifically, so that explanation stays a hypothesis rather than a settled finding.

The same logic shows up in blood pressure medicine. An ACE inhibitor paired with a diuretic lowers blood pressure more than either drug alone, not because the diuretic is a stronger ACE inhibitor, but because it acts on a different part of the system. Retatrutide’s glucagon-receptor activity looks like the same kind of addition: a different lever in the same system.

What two completed phase 3 trials confirmed, and what they left out

Two phase 3 trials have now published results. TRANSCEND-T2D-1 ran 537 adults with type 2 diabetes for 40 weeks and found a dose-dependent HbA1c reduction of 1.12 percentage points on the 12 mg dose, versus 0.81 points on placebo, confirming the pattern the earlier phase 2 trial had already shown^[6]. TRIUMPH-2 ran 1,152 adults with obesity and type 2 diabetes for 80 weeks and confirmed substantial weight loss, 13.8 to 18.8 percentage points better than placebo at the two highest doses, along with the gastrointestinal, hypotension and discontinuation patterns documented in retatrutide’s broader safety record^[7].

What phase 3 didn’t repeat: between them, TRANSCEND-T2D-1 and TRIUMPH-2 enrolled nearly 1,700 people. Neither trial reported a liver-fat scan, a lipid panel or a blood-pressure endpoint^[7][6].

That matters for how much weight to put on everything above this section. A few things the current evidence does not establish:

• These findings are interventional. Every number here comes from randomized, placebo-controlled trials, which support a causal reading inside the trial population. That’s a stronger claim than an observational study could make, but it’s still bounded by the population and duration of the trial that produced it.
• Durability after stopping is unknown. No published retatrutide trial has followed people after they stopped the drug, so whether the liver-fat, lipid or appetite gains persist once the injections stop is not answered anywhere in the published record.
• No regulatory agency has approved retatrutide for anything. Every benefit in this article comes from an investigational drug still moving through trials; none of it carries an approved label yet.

Retatrutide vs semaglutide and tirzepatide on liver fat

Here’s where the triple-receptor story earns its keep. Semaglutide’s own dedicated liver trial, a 48-week, placebo-controlled MRI study in NAFLD, found roughly a 53% relative reduction in liver fat^[8]. Tirzepatide’s SURPASS-3 MRI substudy found roughly a 51% relative reduction at 52 weeks, though that trial compared tirzepatide against insulin degludec rather than placebo, a weaker comparator to beat^[9]. Retatrutide’s own MASLD substudy posted 81% to 82% at 24 weeks, against placebo, in under half the time.

Relative liver fat reduction by drug

• Semaglutide (48 wk, vs placebo): 53
• Tirzepatide (52 wk, vs insulin degludec): 51
• Retatrutide (24 wk, vs placebo): 82

Different trials, different populations and timepoints.

These are three separate trials in three different populations at three different timepoints. Nobody has run this as a head-to-head race, and tirzepatide’s comparator wasn’t even a placebo. Call it a hint rather than a verdict. But a hint that large, in a faster window, against the hardest comparator of the three, is hard to explain away as noise.

The weight-loss number is what gets posted on Reddit. The liver-fat number is the one that deserves to get read twice, and it’s the one no phase 3 trial has gone back to check yet.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.